Viking Therapeutics (VKTX) has captured investor attention with its recent stock movement, delivering a 28% gain over the past month. This comes as traders revisit the company’s ongoing expansion in ...
Viking Therapeutics (VKTX) is back in the spotlight with investors eyeing the company’s advancing clinical pipeline, including its VK2735 obesity drug now in phase 3 trials. Expectations are also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback